Share 'PPMD's Duchenne Drug Development Roundtable Meeting Series, Part 3: Clinical Trial Readiness from the Viewpoint of Clinicians and Infrastructure'
Accelerating trials. Protecting our robust therapeutic pipeline. Ensure as many hits on goal as we can.
Priorities shared by all of us.
And to achieve this, PPMD has convened our industry partners through our Duchenne Drug Development Roundtable and held a series of small, targeted meetings this winter, each focused on another unique element of this equation.
We have been so grateful to the…
You can share this blog post in two ways…
Share this link:
Send it with your computer's email program: Email this